Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-12-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于子公司完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of a business registration change for a wholly-owned subsidiary. It includes details about the subsidiary's updated business license and capital increase. There is no financial data, no report attached or referenced as being published, and no mention of regulatory certifications or voting results. The document is a regulatory announcement about corporate structural changes rather than a financial report or meeting material. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2021-12-27 Chinese
2021年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2021 third extraordinary general meeting of shareholders of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather the official voting results and meeting details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and it is not merely announcing the publication of a report but providing the actual voting results and meeting resolutions.
2021-12-27 Chinese
2021年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2021 third extraordinary general meeting (临时股东大会) of Yunnan Watson Biotechnology Co., Ltd. It details the legal compliance of the meeting's call, attendance, voting process, and results. The document does not contain financial statements or performance data but focuses on the legality and procedural correctness of the shareholder meeting and its resolutions. This type of document is typically associated with the official results of shareholder votes at a general meeting. Given the detailed voting results and legal opinion on the meeting's validity, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and is a legal opinion letter, not a full report or announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is DVA with high confidence.
2021-12-27 Chinese
关于召开2021年第三次临时股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2021 third extraordinary general meeting of shareholders for Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures, registration, and agenda items. There is no financial data or report content, only procedural and logistical details about the shareholder meeting. The document is under 5,000 characters and serves as a notice or announcement for the meeting rather than the meeting materials or results themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. Given the detailed nature and focus on the meeting itself, confidence is high.
2021-12-21 Chinese
关于归还用于暂时补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (839 characters) regarding the return of idle raised funds temporarily used to supplement working capital. It references previous board meetings and disclosures but does not contain financial statements or detailed financial data. It is an update on the use and return of raised capital funds, which fits the category of Capital/Financing Update (CAP). It is not a full financial report or audit, nor is it a regulatory filing or report publication announcement. Therefore, the classification is CAP with high confidence.
2021-12-10 Chinese
第四届监事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Yunnan Watson Biotechnology Co., Ltd. It details decisions made during the 22nd meeting of the 4th Supervisory Board, including termination of H-share issuance plans, approval of guarantees for loans, and issuance of performance bonds. The document is a formal announcement of board meeting resolutions rather than a full report or financial statement. It does not contain financial data or detailed financial analysis, nor is it a transcript or presentation. It is not an annual or interim report, nor an earnings release. It is also not a regulatory filing or certification letter. The content fits best with Board/Management Information (MANG) as it relates to supervisory board decisions and approvals affecting company management and financing activities. The document length is short (1694 characters), consistent with a meeting resolution announcement rather than a full report.
2021-12-10 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.